Beranda › Leukemia Biphenotypic Akut › Tennessee › Knoxville
Uji klinis Leukemia Biphenotypic Akut di Knoxville, TN
3 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi sekitar Knoxville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- East Tennessee Childrens Hospital, Knoxville
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- East Tennessee Childrens Hospital, Knoxville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- East Tennessee Childrens Hospital, Knoxville
Uji klinis Leukemia Biphenotypic Akut di kota lain
- Seattle, WA15 studi
- Houston, TX11 studi
- New York City, NY10 studi
- Atlanta, GA9 studi
- Durham, NC8 studi
- Memphis, TN7 studi
- Chicago, IL7 studi
- Charlotte, NC6 studi
- Baldwin Park, CA6 studi
- Philadelphia, PA6 studi
- Dallas, TX6 studi
- Aurora, CO6 studi
Studi lain di Knoxville
- Kanker Paru Non-Sel Kecil14 studi
- Obesitas10 studi
- Kanker Paru10 studi
- Kanker Payudara9 studi
- Kanker (semua jenis)8 studi
- Kelebihan Berat Badan7 studi
- Gagal Jantung7 studi
- Kanker Metastatik7 studi
- Penyakit Kardiovaskular6 studi
- Melanoma5 studi
- Diabetes Tipe 25 studi
- Tekanan Darah Tinggi5 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.